Following the recent legislation aimed at promoting occupational pension plans as a complement to the public pension system, CEOE and Pérez-Llorca organised a conference to discuss the main institutional aspects and the technical-legal and
Auren has appointed José Antonio García-Argudo (pictured) as a new partner to strengthen the insolvency and restructuring area of the firm. García-Argudo holds a law degree from ICADE and has more than 30 years
Jesús Mas (pictured) has joined Fraternidad-Muprespa Legal Advice and Services Centre as new director, taking over from Rafael Domenech, who recently retired. Mas holds a law degree from the Complutense University of Madrid and
Everything is ready at the Four Seasons hotel in Milan for the fourth edition of Financecommunity Week, the event that every year brings together the community of finance professionals to discuss the industry’s hot
by irina wakstein “The most productive work is the one that comes out of the hands of a happy man”, said the French doctor and writer Victor Pauchet and, although at first it may sound
Gómez-Acebo & Pombo has advised the AD Education Group on the acquisition of a majority stake in Animum Creativity Advanced School in Malaga, the fourth best 3D animation school in the world. With presence
Clifford Chance has advised Cellnex Telecom on the completion of its acquisition of the telecommunications tower assets of CK Hutchison in the United Kingdom (which includes interests in or revenues deriving from up to 6,600 sites,
Faus Moliner has appointed María José López Folgueira (pictured), who until now worked as legal director at Novartis, as the new talent director. The new incorporation of Faus & Moliner has a degree
Garrigues has appointed 16 new partners, 14 in Spain and 2 from international offices, as well as a new partner in G-advisory, the consulting arm offering technical, economic and strategic advice on energy and ESG matters. These
Baker McKenzie client Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system disorders (CNS), and the Neuraxpharm Group, a leading European specialty pharmaceutical company focused on CNS
